Overview

Welcome to Dwaey, specifically on ZYPADHERA 300mg Injection/Powder for page.
This medicine contains an important and useful components, as it consists of Olanzapine (as pamoate monohydrate).
ZYPADHERA 300mg is available in the market in concentration 300mg/Vial and in the form of Injection/Powder for.

LILLY PHARMA FERTIGUNG UND DISTRIBUTION, GmbH & CO. is the producer of ZYPADHERA 300mg and it is imported from GERMANY, The most popular alternatives of ZYPADHERA 300mg are listed downward .

Mode Of Action & Indication

Olanzapine is an atypical antipsychotic with affinity for serotonin 5-HT2A/2C, dopamine, muscarinic M1-M5, histamine H1 and adrenergic ?1 receptors.

Indication

• Schizophrenia
• Bipolar disorder
• Agitation
• Mania

Precaution

Patient w/ cerebrovascular disease or conditions predisposing to hypotension, benign prostatic hyperplasia, paralytic ileus, DM, Parkinson's disease, history of blood dyscrasias, bone marrow depression, hypereosinophilic disorders, myeloproliferative disease, history of seizures or conditions that lower the seizure threshold. IM: Acute MI, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery. Elderly w/ dementia-related psychosis. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and dizziness, if affected, avoid driving and operating machinery. Avoid cigarette smoking. Monitoring Parameters Monitor BP, pulse and resp rate for at least 4 hr after IM inj. Clinical monitoring for hyperglycaemia, plasma lipids and wt. Lactation: Drug enters breast milk; not recommended

Side Effects

• >10% Orthostatic hypotension (>20%)
• Weight gain
• dose dependent (5-40%)
• Hypertriglyceridemia (<39%)
• Hypercholesterolemia (<39%)
• Somnolence
• dose dependent (6-39%)
• Extrapyramidal symptoms (EPS)
• dose dependent (15-32%)
• Xerostomia (9-22%)
• Weakness (2-20%)
• Dizziness (4-18%)
• Accidental injury (12%)
• Insomnia (12%)
• Elevated alanine aminotransferase (ALT) level (5-12%)
• Constipation (9-11%)
• Dyspepsia (7-11%)
• Hyperprolactinemia (30%)
• Hyperglycemia (12.8%) 1-10% Hypotension (2%)
• Postural hypotension (1%)
• Tremor (1%)
• Asthenia (2%)
• Akathisia reactions (2%)
• Parkinsonism reactions (4%) <1% Syncope
• Sudden cardiac death
• Hyperglycemia
• Diabetic coma with ketoacidosis
• Diabetic ketoacidosis
• Acute hemorrhagic pancreatitis
• Venous thromboembolism
• Immune hypersensitivity reaction
• Cerebrovascular disease
• Seizure
• status epilepticus
• Suicidal intent
• Pulmonary embolism
• Death
• Neuroleptic malignant syndrome (NMS)
• Tardive dyskinesia Potentially Fatal: Exacerbation of preexisting diabetes sometimes leading to ketoacidosis. Neuroleptic malignant syndrome.

Contra indication

Angle-closure glaucoma; lactation. IM: History of CVS disease, heart surgery.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks